Drug intelligence / Profile preview

CDR209

Development stage: Preclinical
Lead developer: CDR-Life
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CDR209 is a T-cell engager (TCE) developed by CDR-Life using its proprietary M-gager platform. It is designed to target T-cell receptor beta variable 9 (TRBV9) and CD3 to selectively deplete pathogenic TRBV9-bearing T-cell populations. CDR209 is currently in the discovery stage for the treatment of autoimmune diseases, such as ankylosing spondylitis.

Targets

CD3 (T-cell surface glycoprotein CD3)TRBV9 (T-cell receptor beta variable 9)

Beyond the preview

Go deeper on CDR209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDR209.

Explore the full profile